Nick Mahavir, DPM
Podiatrist · Ocoee, FLNPI 1245225416
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $6,719 of the $11,169 with a category attached, or 60.2%. 32 manufacturers reported payments, led by Triad Life Sciences Inc. at 31.4% of the total. Reporting peaked in 2022 at $3,786 and has fallen 76.6% since, to $885 in 2025. Among podiatrist clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $78.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Triad Life Sciences Inc.$4K
- Medical Device Business Services, Inc.$3K
- Stryker$973
- KCI USA, Inc.$761
- Smith+Nephew$669
- Johnson & Johnson$374
- plus $2K from 26 others
What the payments were for
- Travel & lodging$6,71960%
- Food & beverage$4,45040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Triad Life Sciences Inc. | 11 | $3,510 |
| Medical Device Business Services, Inc. | 19 | $2,688 |
| Stryker | 3 | $973 |
| KCI USA, Inc. | 6 | $761 |
| Smith+Nephew | 23 | $669 |
| Johnson & Johnson | 5 | $374 |
| Paratek Pharmaceuticals, Inc. | 17 | $361 |
| Amgen(2 entities) | 9 | $267 |
| Organogenesis Inc. | 9 | $265 |
| Convatec Inc. | 3 | $179 |
| Flower Orthopedics Coporation | 1 | $150 |
| Kowa Pharmaceuticals America, Inc. | 7 | $130 |
| Merck | 3 | $122 |
| Depuy Synthes Products, Inc. | 1 | $121 |
| Integra Lifesciences Corporation | 4 | $101 |
| Acumed LLC | 2 | $94 |
| Accufix Surgical Inc. | 1 | $68 |
| Bone Support Inc. | 1 | $42 |
| Abbott | 2 | $35 |
| Boston Scientific | 1 | $34 |
| GRT US Holding, Inc. | 2 | $27 |
| Reprise Biomedical, Inc. | 2 | $26 |
| Melinta Therapeutics, LLC | 1 | $26 |
| Zimmer Biomet | 1 | $22 |
| Biocomposites Inc | 1 | $20 |
| Sanara Medtech Inc. | 1 | $20 |
| Mimedx Group, Inc. | 1 | $17 |
| Bioventus LLC | 1 | $17 |
| Lifenet Health | 1 | $14 |
| Nevro Corp. | 1 | $12 |
| Medtronic | 1 | $12 |
| Kerecis Limited | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$3,324
- HOFFMANN$902
- PREVENA$626
- V.A.C. VERAFLO$626
- MOTOBAND$465
- NA$351
- V.A.C. DERMATAC$327
- PROMOGRAN PRISMA$327
- 3M Cavilon$300
- Bair Hugger$300
- 3M Skin and Nasal Antiseptic$300
- REGRANEX$125
- KRYSTEXXA$125
- COLLAGENASE SANTYL$122
- FIBERGRAFT BG Morsels$121
- FIBERGRAFT Aeridyan Matrix$121
- NUZYRA$116
- SIVEXTRO$100
How this compares
$11,169 in reported general payments places this provider in the 90th percentile of 588 podiatrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 23 | $14,091 |
| Pregabalin | 30 | $3,973 |
| Gabapentin | 48 | $1,167 |
| Ciclopirox | 41 | $504 |
| Cephalexin | 31 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $669 | $14,09123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 podiatrist providers in Florida.
Other podiatrist in Ocoee
- James CottomSarasota$1.8M
- Caroline KiserFleming Island$206K
- Adam PerlerLargo$160K
- Desmond BellJacksonville$125K
- Jeffrey KarrLakeland$101K
- Marie WilliamsAventura$96K
- Todd BrennanTampa$88K
- Robert HooverLake Mary$71K
- Daniel BrandweinPompano Beach$70K
- John TorregrosaMiami$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.